“辉瑞公司生产的马塔西单抗，两年多前才在美国获批上市。此次落地乐城瑞金海南医院的首针是美国之外全世界所有国家中的第一针。”瑞金海南医院党委书记、院长顾志冬表示，马塔西单抗成功落地离不开各方单位的支持，截至目前，医院已落地近170项特许药械项目。接下来 ...

2024年12月，辉瑞终止了与Sangamo Therapeutics在A型血友病基因疗法giroctocogene fitelparvovec的合作，将该基因治疗的权益退还给了Sangamo。 近日，基因治疗先驱公司蓝鸟更是在连续几年的挣扎后， ...

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

CARBONDALE — The coolest event of the year — the Law Enforcement Torch Run Polar Plunge to benefit Special Olympics Illinois athletes — returns at 11 a.m. Saturday, Feb. 22.

为解决胰腺癌预后差、诊断和治疗难题，“G. d’ Annunzio” 大学的研究人员开展蛋白质组学荟萃分析研究。他们发现相关通路及上游调节因子，这为胰腺癌诊疗研究提供新思路，推荐科研读者阅读。

例如，Glypican - 3 与 TFPI 的选择性合作，能够促进移植的造血干细胞归巢到骨髓并成功植入，而 Glypican - 1 则没有这种功能。B 细胞和 T 细胞前体表达的 Syndecans，通过与细胞粘附分子、ECM 成分和促进运动的因子相互作用，参与了造血细胞的迁移过程。 研究还发现 ...